About
Overview
Company Leadership
Science
Technology Platform
Scientific Publications
Pipeline
Overview
CF101
CF102
CF602
Investor Information
Overview
News / Events
Company Information
Financial Information
Stock Information
SEC Filings
Corporate Governance
Shareholders Meetings
Contact Us
Directions
Investor Information
Overview
News / Events
Press Releases
In The News
Research
Events Calendar
Presentations
Email Alerts
Company Information
Profile
Management
IR Contacts
FAQ
Financial Information
Quarterly & Annual Reports
Stock Information
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Section 16 Filings
Corporate Governance
Board of Directors
Governance Docs
Shareholders Meetings
Email Alerts
IR Contacts
RSS News Feed
Press Releases
All News
By Year:
2020
2019
2018
2017
2016
2015
2014
2013
2012
Nov 30, 2018 7:00 AM EST
Can-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update
Nov 20, 2018 7:00 AM EST
Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert
Oct 31, 2018 7:00 AM EDT
Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19
Oct 25, 2018 7:00 AM EDT
Can-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference
Oct 18, 2018 7:00 AM EDT
Can-Fite CEO to present as Expert Speaker on Namodenoson at NASH Summit Europe 2018
Sep 12, 2018 7:00 AM EDT
Can-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases (AASLD)
Sep 4, 2018 7:00 AM EDT
Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year
Aug 31, 2018 7:00 AM EDT
Can-Fite Reports Second Quarter 2018 Financial Results and Provides Clinical Update
Aug 29, 2018 7:00 AM EDT
Can-Fite BioPharma Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
Aug 21, 2018 7:00 AM EDT
Can-Fite Announces Enrollment of First Patient in its Comfort™ Phase III Trial of Piclidenoson in Psoriasis
<< Previous
1...
5
6
7
8
9
10
11
12
13
14
...29
Next >>
Show All
